BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The goal of this research study is to find the safest and most effective dose of the study
drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome
(MDS).
The names of the study drugs involved in this study are/is:
- BXCL701